USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ENERGESIS PHARMACEUTICALS, INC.
City: BOSTON
State: MA
Zip+4: 02199-7723
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $168,876.00 1
STTR Phase I $98,942.00 1
STTR Phase II $749,692.00 1

Award List:

Cell Culture Approaches to Generating Brown Adipose Tissue for Autologous Transplantation

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency / Branch: DOD / ARMY
Research Institution: Boston University
Principal Investigator: Olivier Boss, Chief Scientific Officer – (617) 959-2322
Award Amount: $98,942.00
RI Contact: Stephen R. Farmer
Abstract:
Obesity and its associated metabolic complications including diabetes are becoming increasingly prevalent in the general population as well as in military personnel. Brown adipose tissue (BAT) is a major site of energy expenditure through thermogenesis, which is mediated by the mitochondrial… More

Human Brown Adipocyte Transplantation and In Vivo Metabolic Characterization

Award Year / Program / Phase: 2012 / STTR / Phase II
Agency / Branch: DOD / ARMY
Research Institution: Boston University
Principal Investigator: Olivier Boss, Chief Scientific Officer – (617) 959-2322
Award Amount: $749,692.00
RI Contact: Stephen R. Farmer
Abstract:
Obesity and its associated metabolic complications including diabetes are becoming increasingly prevalent in the general population as well as in military personnel. Brown adipose tissue (BAT) is a major site of energy expenditure through thermogenesis, which is mediated by the mitochondrial… More

Radioactive Stents for Brachytherapy of Esophageal Cancers

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Olivier Boss – 617-947-9773
Award Amount: $168,876.00
Abstract:
DESCRIPTION (provided by applicant): Obesity has reached epidemic proportions in the U.S. and plays a major role in the development of type 2 diabetes, dyslipidemia, and cardiovascular disease. There remains a very significant need for better non- surgicaltreatments. While most weight loss agents… More